Why the study?
Does prophylactic CEA or CAS prevent stroke in asymptomatic patients with carotid disease?
Does prophylactic CEA or CAS prevent stroke in asymptomatic patients with carotid disease?
The management of asymptomatic carotid disease remains controversial, with prophylactic intervention likely benefiting only a small subset of high-risk patients.
The inescapable conclusion is that only a relatively small proportion of asymptomatic patients benefit from prophylactic CEA/CAS. The key question, therefore, remains; is society prepared to invest sufficient resources in identifying these 'high risk for stroke' patients so that they can benefit from aggressive BMT and CEA or CAS, leaving the majority of lower risk patients to be treated medically?
No takes yet. Share an insight, caveat, or question.
A.R. Naylor (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: